Roberts Brandi 4

What Happened

• Brandi Roberts, Chief Financial Officer of Definium Therapeutics (DFTX), was reported as acquiring 62,500 shares on 2026-06-22 via an award/grant (Form 4 code "A"). The filing shows an acquisition price of $0.00 (total reported value $0), reflecting a performance-based grant rather than a cash purchase.

Key Details

• Transaction date and price: 2026-06-22; 62,500 shares @ $0.00 per Form 4.
• Shares owned after transaction: not disclosed in this filing.
• Footnote: These common shares represent the first tranche of performance share units (PSUs) granted effective June 2, 2025, and remain subject to vesting based on Roberts' continued employment through June 2, 2028. Each PSU is a contingent right to receive one common share and vests only upon achievement of specified clinical and regulatory milestones per the Performance Share Unit Award Agreement.
• Filing timeliness: Reported on 2026-06-22 for the 2026-06-22 transaction; no late-filing flag indicated.

Context

• This was an award of PSUs (contingent equity), not an open-market purchase or sale. PSUs do not represent immediately tradable shares until vesting and milestone conditions are satisfied, so they are compensation-linked and contingent on both service and performance.